Sangamo Therapeutics, Inc.
SGMO
$0.4914
$0.00831.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -79.45M | -97.94M | -134.84M | -249.68M | -328.05M |
| Total Depreciation and Amortization | 8.76M | 9.36M | 10.24M | 15.53M | 19.14M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.74M | 15.54M | 18.94M | 67.63M | 114.44M |
| Change in Net Operating Assets | 13.33M | 5.90M | -8.66M | -6.86M | -12.72M |
| Cash from Operations | -44.63M | -67.14M | -114.33M | -173.38M | -207.21M |
| Capital Expenditure | -267.00K | -267.00K | -2.79M | -5.42M | -10.96M |
| Sale of Property, Plant, and Equipment | 1.95M | 1.95M | 475.00K | 127.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 35.84M | 76.22M | 116.59M | 164.60M |
| Cash from Investing | 1.68M | 37.52M | 73.91M | 111.30M | 153.64M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 17.57M | 29.74M | 22.74M | 22.74M | 29.45M |
| Repurchase of Common Stock | -3.18M | -1.36M | -1.19M | -1.09M | -746.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 14.39M | 28.38M | 21.55M | 21.66M | 28.71M |
| Foreign Exchange rate Adjustments | -101.00K | -2.05M | 1.55M | -124.00K | 446.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -28.65M | -3.29M | -17.31M | -40.54M | -24.41M |